Accelerating proof of concept for small molecule drugs using solid-state chemistry.
In this perspective we have shown that the process of "proof of concept" (POC) in the early part of drug development can be greatly accelerated by close attention to the underlying solid-state chemistry (SSC) of a new chemical entity. POC seeks data that provide confidence in the therapeutic activity and safety of a new chemical entity, which can rapidly lead to a key "GO/NO-GO" decision point for further development. Due to the high cost of the development of new chemical entities and the current low overall productivity of obtaining successful candidates, the pharmaceutical industry is being required to develop accelerated POC strategies. The success of accelerated approaches to POC depends on a full understanding of the SSC of drugs in relation to solubility and stability. Dissolution-limited absorption due to poor solubility of drug substances is particularly important because it can lead to low exposure in animals and undesired bioavailability in humans. Choosing a desirable solid form with sufficient solubility and acceptable stability is essential in developing formulations for POC with superior quality. In this perspective we present an approach that utilizes SSC as part of a novel 2-year development strategy for reaching the pivotal clinical trial stage of development.
Byrn
Stephen R
SR
Department of Industrial and Physical Pharmacy, Purdue University, 575 Stadium Mall Drive, West Lafayette, Indiana 47907-2091, USA. sbyrn@pharmacy.purdue.edu
Zografi
George
G
Chen
Xiaoming  Sean
X
D000818:Animals; D002626:Chemistry, Pharmaceutical / Q000639:trends; D002986:Clinical Trials as Topic; D003460:Crystallization / Q000639:trends; D055808:Drug Discovery / Q000639:trends*; D006801:Humans; D004364:Pharmaceutical Preparations / Q000737:chemistry*; D012995:Solubility
D004364:Pharmaceutical Preparations